# A Prospective Non-interventional Study in Overactive Bladder (OAB) Patients Prescribed Betmiga® as Part of Routine Clinical Practice

> **NCT02320773** · — · COMPLETED · sponsor: **Astellas Pharma Europe Ltd.** · enrollment: 863 (actual)

## Conditions studied

- Urgency Incontinence
- Urinary Bladder Overactive
- Overactive Bladder
- Urologic Diseases
- Urinary Bladder Diseases

## Interventions

- **DRUG:** Betmiga®

## Key facts

- **NCT ID:** NCT02320773
- **Lead sponsor:** Astellas Pharma Europe Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2014-11-25
- **Primary completion:** 2016-07-27
- **Final completion:** 2016-07-27
- **Target enrollment:** 863 (ACTUAL)
- **Last updated:** 2024-10-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02320773

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02320773, "A Prospective Non-interventional Study in Overactive Bladder (OAB) Patients Prescribed Betmiga® as Part of Routine Clinical Practice". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02320773. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*